Hematology

Data from phase 3 study of leniolisib in APDS published

Results of a phase 3 clinical trial published in the journal Blood demonstrated the efficacy of the investigational drug leniolisib in patients with activated phosphoinositide 3-kinase delta syndrome (APDS). Leniolisib is an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. In the study, 31 patients with APDS were randomly assigned 2:1...